All Type of News
Toujeo & Jardiance landed in Samsung Medical Center
22 new pharmaceutical products, such as Sanofi-Aventis’ next-generation basal insulin Toujeo and Boehringer Ingelheim’s Jardiance, succeeded in newly landing in Samsung Medical Center.
According to the industry con...
Novartis Korea still with no apology for rebate crisisNovartis Korea avoided responsibility for the recent rebate crisis instead of making an apology.
Assemblyperson Mi-Hyuk Kwon from The Minjoo Party demanded an apology from CEO ...
|
MOHW, “Based on Novartis case, we will conduct administrative inspections on multinational pharmas”
The Ministry of Health and Welfare(MOHW) will conduct administrative inspections related to rebate on multinational pharmaceutical companies.
Minister Jin-Yup Jung of Health and Welfare announced the ministry will c...
“Janssen Korea violated Narcotics Control Law by advertising ‘Concerta’ to public”An argument was made a multinational pharmaceutical company Janssen Korea was confirmed to violate the Narcotics Control Law for conducting marketing campaigns on people to incr...
|
Pharma industry on first day to enforce Bribery Prohibition Law
On the 28th, the Bribery Prohibition Law will be actively enforced.
It has been 4 years since the Anti-Corruption and Civil Rights Commission gave an administrative notice for the legislation of the act on August 201...
Rapidly enlarging dementia treatment market, attracting domestic companies too
Encountering the rapid aging society, overcoming dementia for elders has become a huge social issue. An increasing number of dementia patients enlarges its market; thus, the Alzheimer’s disease market accounting for 5...
Will enlargement of companies be a solution to distribution industry’s security issue?
In order to address the security problem, one of the biggest burdens among domestic pharmaceutical distribution companies, it seems enlargement must be proceeded.
This is because securities have naturally disappeare...
Samsung applies for approval of Humira biosimilar
Samsung is about to secure a pipeline with biosimilars of the top 3 ‘TNF-alpha inhibitors.’
After a ‘Enbrel(etanercept)’ similar, ‘Lenflexis,’ and a ‘Remicade(infliximab)’ similar, ‘Brenzys,’ the company filed for a...
‘Pradaxa 75mg’ approval voluntarily withdrawn due to insufficient usage
Boehringer Ingelheim was confirmed to voluntarily withdraw Korean approval of the low volume of its novel oral anticoagulant, ‘Pradaxa(generic name: dabigatran).’ It has been a year since it acquired the approval on A...
‘Kanarb’ shows off in front of circulatory system experts around the world
A Korean new drug Kanarb in the hypertension market is challenging to the global market beyond the Korean market. The drug is expected to be called the first Korean global drug recognized by both of the Korean and for...
